Immunosuppressive effects of vascular endothelial growth factor.
T-cell
anti-angiogenesis
dendritic cell
immunosuppression
vascular endothelial growth factor
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
05
2022
accepted:
26
07
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Vascular endothelial growth factor (VEGF) serves a critical role in vasculogenesis, angiogenesis, tumor, inflammatory angiogenesis and lymphangiogenesis. Since 2004, bevacizumab (Avastin), a humanized anti-VEGFA monoclonal antibody, has been approved for the treatment of non-small cell lung, breast, kidney and ovarian cancer in combination with standard chemotherapy. VEGF has been demonstrated to be important in the clinic as a therapeutic target in the anti-angiogenic approach to cancer therapy. The targeting of VEGF, together with immunotherapy, has been reported to be able to reverse the immunosuppressive effects of VEGF. A positive correlation between VEGF expression and the reduced survival rates of patients with cancer has also been demonstrated. Furthermore, increased VEGF expression can lead to immune suppression via the inhibition of dendritic cell maturation, the reduction of T-cell tumor infiltration and the promotion of inhibitory cell types in the tumor microenvironment.
Identifiants
pubmed: 36238855
doi: 10.3892/ol.2022.13489
pii: OL-24-04-13489
pmc: PMC9494354
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
369Informations de copyright
Copyright: © Ribatti et al.
Déclaration de conflit d'intérêts
The author declares that they have no competing interests.
Références
Cancer Res. 2013 Jan 15;73(2):539-49
pubmed: 23108136
Oncotarget. 2014 Apr 30;5(8):2208-20
pubmed: 24809734
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
Cancer Immunol Immunother. 2007 Jun;56(6):761-70
pubmed: 17086423
J Immunol. 1998 Feb 1;160(3):1224-32
pubmed: 9570538
Trends Pharmacol Sci. 2009 Dec;30(12):624-30
pubmed: 19836845
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
J Immunol. 2010 Jan 15;184(2):545-9
pubmed: 20008289
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6
pubmed: 23045683
Leukemia. 2004 Oct;18(10):1656-61
pubmed: 15343347
Int J Mol Sci. 2018 Apr 24;19(5):
pubmed: 29695053
J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):140-4
pubmed: 11501971
Br J Cancer. 2009 Apr 7;100(7):1111-9
pubmed: 19277038
Oncology. 2010;79(3-4):187-96
pubmed: 21358206
Blood. 2007 Jul 15;110(2):624-31
pubmed: 17376891
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4
pubmed: 12516033
J Immunol. 2008 Jul 1;181(1):346-53
pubmed: 18566400
Nat Biotechnol. 2007 Aug;25(8):911-20
pubmed: 17664940
Blood. 2003 Jun 15;101(12):4878-86
pubmed: 12586633
Br J Cancer. 2012 Nov 20;107(11):1869-75
pubmed: 23169339
Sci Transl Med. 2020 Mar 11;12(534):
pubmed: 32161104
Front Immunol. 2018 May 03;9:978
pubmed: 29774034
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Cancer Res. 2010 Aug 1;70(15):6171-80
pubmed: 20631075
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Oncoimmunology. 2015 Jan 22;4(4):e998519
pubmed: 26137414
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
J Immunol. 2007 Feb 1;178(3):1505-11
pubmed: 17237399
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
FASEB J. 2006 Apr;20(6):621-30
pubmed: 16581970
Science. 1983 Feb 25;219(4587):983-5
pubmed: 6823562
Cancer Immunol Immunother. 2008 Aug;57(8):1115-24
pubmed: 18193223
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Cell Death Discov. 2016 Oct 03;2:16025
pubmed: 27752361
J Immunol. 2005 Jan 1;174(1):215-22
pubmed: 15611243
Cancer J. 2018 Jul/Aug;24(4):193-204
pubmed: 30119083
Clin Cancer Res. 2009 Mar 15;15(6):2148-57
pubmed: 19276286
Cancer Immunol Immunother. 2015 Oct;64(10):1241-50
pubmed: 26105626
Sci Immunol. 2019 Nov 8;4(41):
pubmed: 31704735
J Pathol. 2012 May;227(1):17-28
pubmed: 22262122
Oncotarget. 2016 Jul 1;7(31):50277-50289
pubmed: 27385210
Anticancer Res. 2009 Mar;29(3):881-8
pubmed: 19414323
Int J Cancer. 1999 Jan 18;80(2):315-9
pubmed: 9935216
Int Immunopharmacol. 2011 Jul;11(7):856-61
pubmed: 21315783
Sci Adv. 2020 Jan 31;6(5):eaay4458
pubmed: 32064351
Sci Adv. 2019 Dec 04;5(12):eaaw3851
pubmed: 31840053
Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124
pubmed: 29229461
Cancer Res. 2009 Mar 15;69(6):2514-22
pubmed: 19276342
Int J Cancer. 2012 Feb 15;130(4):857-64
pubmed: 21445972
Nat Immunol. 2007 Mar;8(3):239-45
pubmed: 17304234
J Immunol. 2016 Nov 15;197(10):3927-3935
pubmed: 27815442
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1478-83
pubmed: 23766387
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Science. 2019 Aug 9;365(6453):544-545
pubmed: 31395771
Int Immunol. 2000 May;12(5):671-6
pubmed: 10784613